Announcements
- argenx Reports First Quarter 2024 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2024 Health Care Conference
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
- argenx Announces Annual General Meeting of Shareholders on May 7, 2024
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- argenx to Present at Upcoming Investor Conferences
More ▼
Key statistics
As of last trade argenx SE (ARGNF:PKL) traded at 373.50, 9.53% above its 52-week low of 341.00, set on Dec 20, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 373.50 |
---|---|
High | 373.50 |
Low | 373.50 |
Bid | -- |
Offer | -- |
Previous close | 373.50 |
Average volume | -- |
---|---|
Shares outstanding | 59.43m |
Free float | 59.36m |
P/E (TTM) | -- |
Market cap | 20.30bn EUR |
EPS (TTM) | -5.25 EUR |
Data delayed at least 15 minutes, as of May 14 2024 16:12 BST.
More ▼